About Nuuvera
Nuuvera is a global cannabis company founded on Canadian principles, and built with the whole world in
mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring
opportunities in several other countries, to develop commercial production and global distribution of
medical grade cannabis in legalized markets. Through its subsidiaries, ARA – Avanti Rx Analytics Inc.
and Avalon Pharmaceutical Inc., Nuuvera holds a Dealer License (GMP) under the Narcotic Control
Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health
Canada review process to become a Licensed Producer.
Nuuvera was incorporated on January 30, 2017 under the Business Corporations Act (New
Brunswick) as Nuuvera Corp. and continued under the Canada Business Corporations Act on
March 8, 2017. Nuuvera, through its subsidiaries, is currently engaged in the testing, analysis,
formulation and extraction of cannabis and cannabis derivative products in Canada, with a view
to the future commercial sale of such products, and is pursuing opportunities in various other
legal international jurisdictions (excluding the United States).
Nuuvera holds an indirect 51% interest in ARA-Avanti Rx Analytics Inc. (“Avanti”). Avanti is a
Health Canada Good Manufacturing Practices (“GMP”), Office of Controlled Substances and
Natural Health Products approved organization, which offers a comprehensive array of services
in the field of controlled drugs and substances ranging from analytical R&D and quality control
testing (including cannabinoids and terpene profiling and quantification, moisture analysis,
residual solvents analysis, heavy metals elemental analysis, pesticides analysis and
quantification), marihuana and hemp multi extraction processes under a compliant, safe and
controlled environment, cannabinoids refinement and purification, commercial formulation,
production and packaging of cannabis infused-products such as oils and capsules, cannabis waste
management by means of material denaturation, as well as quality assurance and regulatory
consulting and commercial controlled substances importation and exportation. Avanti does not
grow cannabis. Avanti conducts its business through: (a) a broad, innovative portfolio of
platform-based technologies; (b) a team of experienced personnel; (c) advanced research and
development and formulation capabilities; and (d) a 22,000 square foot analytical laboratory,
production and extraction facility. Avanti holds a Dealer Licence for the entire spectrum of
cannabis and cannabinoid controlled substances. Permitted activities under this licence include possession, production, packaging, sale and delivery of these controlled substances. Avanti also
possesses a drug establishment licence under the Food and Drug Regulations (Canada), which
evidences its GMP status.
Avalon Pharmaceuticals Inc. (“Avalon”), an indirect, wholly-owned subsidiary of Nuuvera, is a
late stage Licensed Producer applicant under the Access to Cannabis for Medical Purposes
Regulations. Health Canada has granted Avalon permission to proceed with the construction of
its cultivation facility located in Brampton, Ontario and Avalon anticipates completion and full
production in Q2 2018.
Nuuvera has also entered into a strategic partnership with Aphria Inc. (“Aphria”) which includes
a cannabis supply agreement for Nuuvera to purchase up to 1,500 kg of cannabis, growing to
5,000 kg when Aphria completes its phase III expansion, then to 17,000 kg when Aphria
completes its phase IV expansion in 2018, until Nuuvera’s own greenhouse facility is complete,
as well as an outsourced 1 million square foot “contract grow” facility to
be built and operated by Aphria in Leamington, Ontario.
News 
Market Data 
Discover 
